Article
Community Oncology Alliance (COA) submitted formal comments to CMS in support of proposed changes to the 340B Drug Discount Program and site-neutral paymnts put forward in the Hospital Outpatient Prospective Payment (HOPPS) rule. However, they also submitted comments warning against proposals to introduce new third-party middlemen to the Part B system.
The Community Oncology Alliance (COA) submitted formal comments to CMS in support of the agency's proposed additional changes to the 340B Drug Discount Program. They also voiced support for the site-neutral payments proposed in the Hospital Outpatient Prospective Payment (HOPSS) rule for 2019, which they say will address "tremendous Medicare Part B spending increases that have resulted from the growing shift of care from independent community practices to hospital outpatient departments."
However, COA did caution against proposals for introducing new third-party middlemen to the Part B system, saying it would have a negative impact on patient care.
Read the comments in full here.